1-15 of 65
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
CME/CEImproving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE
Samir Dalia, MD
Christopher Jurief
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Molecular Profiling as a Cornerstone of Precision AML Therapy
MinuteCE®Molecular Profiling as a Cornerstone of Precision AML Therapy
Ghayas Issa, MD
Amir Fathi, MD
Menin Inhibitors: Biologic and Clinical Rationale
MinuteCE®Menin Inhibitors: Biologic and Clinical Rationale
Ghayas Issa, MD
Amir Fathi, MD
Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
MinuteCE®Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
Ghayas Issa, MD
Amir Fathi, MD
- advertisement
Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
MinuteCE®Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
Ghayas Issa, MD
Amir Fathi, MD
Managing Adverse Events Associated With Menin Inhibitors
MinuteCE®Managing Adverse Events Associated With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Emerging Directions in Menin-Directed AML Therapy
MinuteCE®Emerging Directions in Menin-Directed AML Therapy
Ghayas Issa, MD
Amir Fathi, MD
Ongoing Clinical Trials in AML With Menin Inhibitors
MinuteCE®Ongoing Clinical Trials in AML With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
- advertisement
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Differential Diagnosis of Indolent Systemic Mastocytosis
MinuteCE®Differential Diagnosis of Indolent Systemic Mastocytosis
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
